Genelux (GNLX) Interest Expenses (2022 - 2023)
Genelux (GNLX) recorded quarterly Interest Expenses of $6000.0 in Q4 2023, down 85.71% quarter-over-quarter from $42000.0 in Q3 2023, and down 97.94% on a YoY basis from $291000.0 in Q4 2022.
Genelux (GNLX) Interest Expenses (2022 - 2023) Analysis & Trends
Genelux's Interest Expenses history runs 2 years deep, the most recent figure standing at $6000.0 for Q4 2023.
- In Q4 2023, Interest Expenses fell 97.94% year-over-year to $6000.0; the TTM figure through Sep 2024 stood at $6000.0 (down 99.83% YoY), while the FY2023 annual figure was $173000.0, down 84.96% from the prior year.
- Interest Expenses was $6000.0 for Q4 2023 at Genelux, down from $42000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $3.1 million in Q1 2023 to a low of $6000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 42,000.00 |
| Sep 30, 2023 | 42,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 3.11 Mn |
| Mar 31, 2023 | 3.11 Mn |
| Dec 31, 2022 | 291,000.00 |
| Dec 31, 2022 | 291,000.00 |
| Sep 30, 2022 | 286,000.00 |
| Sep 30, 2022 | 286,000.00 |
| Mar 31, 2022 | 288,000.00 |
| Mar 31, 2022 | 288,000.00 |